fig4

From: Changes in hepatic fibrosis and incidence of HCC following direct-acting antiviral treatment of F3 chronic hepatitis c patients: a prospective observational study

Changes in hepatic fibrosis and incidence of HCC following direct-acting antiviral treatment of F3 chronic hepatitis c patients: a prospective observational study

Figure 4. Cumulative hazard of HCC in patients with HCV after the end of DAA therapy, shown by Cox regression model according to fibrotic changes after DAA. Cum: Cumulative; HCC: hepatocellular carcinoma; HCV: hepatitis C virus; DAA: direct acting antiviral.

Hepatoma Research

ISSN 2454-2520 (Online) 2394-5079 (Print)

editorialoffice@hrjournal.net

Navigation

Sitemap